From the 1Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland; 2Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; 3University of Washington School of Public Health and Community Medicine, Department of Epidemiology, Seattle, Washington; 4Department of Pathology, University of Washington, Seattle, Washington; 5Public Health - Seattle/King County, Washington; and 6Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland.
See related editorial on page 246.
* For a complete list of members of The Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group, see the Appendix.
Supported by the intramural program of the National Cancer Institute, National Institutes of Health, Department of Health and Human Services and contracts CN-55153, CN-55154, CN-55155, CN-55156, CN-55157, CN-55158, CN-55159, and CN-55105.
Some of the equipment and supplies used in this study were donated or provided at reduced cost by Digene Corporation (Gaithersburg, MD), Cytyc Corporation (Marlborough, MA), National Testing Laboratories (Fenton, MD), Denvu (Tucson, AZ), TriPath Imaging, Inc. (Burlington, NC), and Roche Molecular Systems, Inc. (Alameda, CA).
This article is a U.S. Government work and, as such, is in the public domain in the United States of America. The views expressed in this document are those of the authors and do not necessarily reflect those of the National Cancer Institute, National Institutes of Health or the U.S. Department of Health and Human Services.
Corresponding author: Vivien Webb Hanson, MD, University of Washington School of Public Health and Community Medicine, Department of Epidemiology, 4032 Burton Place West, Seattle, WA 98199; e-mail: [email protected].
